Technology | April 19, 2012

FDA Clears GE’s Q. Freeze for PET/CT to Better Assess Cancer Treatment Response

Q.Freeze imaging technology can eliminate a patient’s respiratory motion within PET/CT imaging, potentially saving healthcare costs

April 19, 2012 — GE Healthcare this week announced it has received U.S. Food and Drug Administration (FDA) clearance of Q.Freeze, one of the positron emission tomography/computed tomography (PET/CT) quantitative imaging technologies designed to enable treatment evaluation earlier in a patient’s cancer treatment.

Q.Freeze combines the quantitative benefits of 4-D phase-matched PET/CT imaging, MotionMatch, into a single static image. By collecting CT and PET data at each phase of the breathing cycle, then matching the data for attenuation correction purposes, Q.Freeze is designed to improve quantitative consistency compared to conventional static PET imaging techniques while facilitating the reading of the 4D PET/CT imaging. None of the acquisition data is wasted, as 100 percent of the counts collected are combined to create a single static image. The goal is an image that has the dual benefit of frozen patient respiratory motion and reduced image noise.

The spark behind the idea — which has been under development since 2006 — was that correcting for lesion movement tied to respiratory motion at the same comfort and dose level as a routine static procedure would support clinicians’ diagnostic confidence. Because patients may not breathe the same way as they might have during their baseline study, Q.Freeze could help enable easy and proper longitudinal response to therapy comparisons.

“GE Healthcare has demonstrated its excellence in addressing one of the biggest clinical challenges in PET/CT: respiratory motion” said Michael Barber, vice president and general manager, molecular imaging, GE Healthcare. “Respiratory motion impacts image clarity and quantification accuracy of lesions in organs subject to respiratory motion, such as the lung, liver and pancreas. Now with Q.Freeze, GE Healthcare is offering an innovative technology that makes patient respiratory motion correction a routine procedure for every scan.”

In a recent study by Cristina Messa, head of the nuclear medicine department, and Luca Guerra, nuclear medicine physician of the Center for Molecular Bioimaging and San Gerado Hospital (HSG-CBM) in Monza, Italy, a patient underwent PET/CT for nodule characterization. Their findings included a comparison of static acquisition, 4-D PET/CT acquisition and Q.Freeze acquisition to determine clear evidence of a metabolic lesion. The Q.Freeze acquisition was able to increase image quality, making the lesion easily identifiable. According to the doctors, this improvement leads to a potential workflow benefit, allowing the physician to review only one set of images free of a patient’s respiratory motion.

Q.Freeze is included in the GE Healthcare Q.Suite, a collection of next-generation capabilities designed to further quantitative PET by generating more consistent standardized uptake value (SUV) readings — enabling clinicians to assess treatment response accurately. During the course of cancer treatment, clinicians traditionally gauge progress by looking for physical change in the size of a tumor, typically using computed tomography (CT) or magnetic resonance (MR). However, with quantitative PET imaging, they are also able to consider a tumor’s metabolic activity. In many cases, metabolic changes in a tumor can be perceived earlier than physical ones; thus quantitative PET can give physicians an earlier view of how well a treatment is working.

For quantitative PET to be effective, consistency of SUV measurements between a patient’s baseline scan and subsequent follow-up scans is critical. Variation can occur throughout the PET workflow, in areas from patient management and biology to equipment protocols and performance. Controlling these variables to increase consistency can improve the clinician’s confidence that an SUV change has true clinical meaning.

“Doctors are seeking quantitative tools, such as Q.Freeze, to obtain reproducible measurements over a longitudinal patient study. Q.Freeze is one of the first element of a suite of tools that may enable doctors to assess confidently biological changes in a patient during a course of treatment, allowing them to quickly and accurately modify treatment regimens,” said Vivek Bhatt, general manager, PET/CT, GE Healthcare. “These tools, ultimately, could potentially contribute to personalized oncology care, increase quality of patient care and reduce wasted expenditure on ineffective treatment.”

For more information: www.gehealthcare.com

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init